BioCentury | Jan 21, 2021
Management Tracks

MacDonald to succeed retiring Ostrach as Dynavax CFO; plus Antibiotic Resistance UK, Arix, Viridian, Avrobio, Imago, ONL, Atea, Chiasma, Tiziana, Elevar,  and Imara

...to depart. Anderson is now a partner at Sofinnova Partners.Matthew Plunkett joined myeloid disease company Imago BioSciences Inc....
...of medical research at Acceleron Pharma Inc. (NASDAQ:XLRN).TARGETSFASN (FAS) – Fatty acid synthase BC Staff Dynavax Technologies Corp. Avrobio Inc. Imago BioSciences Inc. ONL...
BioCentury | Nov 20, 2020
Finance

Nov. 19 Quick Takes: Olema’s IPO, plus venture rounds for Imago, Medable,  China deal for AUM-Newsoara and Qiming’s $1.2B fund

...it raised a $54 million crossover round in July.Imago raises $80M series CMyeloproliferative disease company Imago BioSciences Inc....
...Estrogen receptor 2LSD1 (KDM1A) – Lysine-specific demethylase 1 BC Staff Medable Inc. Olema Pharmaceuticals Inc. AUM Biosciences Pte. Ltd. Imago BioSciences Inc. Newsoara...
BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

...see "STING Start-Up STipe First to Emerge from Novo Incubator" ). Bone marrow disease play Imago BioSciences Inc....
...Therapeutics Inc. TCR2 Therapeutics Inc. Five Prime Therapeutics Inc. Evelo Biosciences Inc. Ohana Biosciences Magenta Therapeutics Inc. Mesa Biotech Inc. Orexo AB STipe Therapeutics Imago BioSciences Inc. Cinclus...
BioCentury | Nov 5, 2019
Company News

Management tracks: Santhera, Acadia, Aeglea, Entrada, Kleo, Laboratory for Advanced Medicine, Imago, Glympse and Cognition

...was EVP and general manager of AncestryDNA subsidiary of Ancestry LLC. Bone marrow disease play Imago BioSciences Inc....
...CFO. He was EVP of finance at Enzo Biochem Inc. (NYSE:ENZ). BioCentury Staff Cognition Therapeutics Inc. Glympse Bio Inc. Imago BioSciences Inc. Laboratory...
BioCentury | Jul 19, 2019
Company News

Management tracks: Iovance, ViiV, Hercules, Pappas and more

...and hired Alain Delcayre as SVP of research. Rienhoff is the founder and CEO of Imago BioSciences Inc....
BioCentury | Mar 21, 2019
Financial News

Imago to deploy $40M series B for Phase II trials

...to support completing Phase II trials of its lead compound, IMG-7289, for hematological indications. An Imago BioSciences Inc....
...Ventures Fund and Clarus Ventures. Omega Funds' Dina Chaya will join Imago's board. Sandi Wong, Staff Writer IMG-7289 Imago BioSciences Inc. Omega...
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...Ricolinostat (ACY-1215) Histone deacetylase 6 (HDAC6) Peripheral neuropathy Start Phase II October 2017 Undisclosed Undisclosed Imago BioSciences Inc....
BioCentury | Nov 10, 2016
Clinical News

IMG-7289: Ph I/II started

...I portion will identify the selected dose of IMG-7289 for the dose-expansion Phase II portion. Imago BioSciences Inc....
...leukemia (AML) and myelodysplastic syndrome (MDS) Endpoint: Safety; pharmacokinetics Status: Phase I/II started Milestone: NA Alicia Parker IMG-7289 Imago BioSciences Inc. Lysine-specific...
BioCentury | Jun 15, 2015
Finance

Products, hold the platform

...three investments - all on the traditional venture side. These include Annexon Bioscience Inc. , Imago BioSciences Inc....
...Avillion LLP, London, U.K. Clarus Ventures, Cambridge, Mass. Eisai Co. Ltd. (Tokyo:4523; Osaka:4523), Tokyo, Japan Imago BioSciences Inc....
BioCentury | Nov 10, 2014
Finance

Imago-in' places

...The team at Imago BioSciences Inc. raised a $26.5 million series A round geared to helping them repeat...
Items per page:
1 - 10 of 12
BioCentury | Jan 21, 2021
Management Tracks

MacDonald to succeed retiring Ostrach as Dynavax CFO; plus Antibiotic Resistance UK, Arix, Viridian, Avrobio, Imago, ONL, Atea, Chiasma, Tiziana, Elevar,  and Imara

...to depart. Anderson is now a partner at Sofinnova Partners.Matthew Plunkett joined myeloid disease company Imago BioSciences Inc....
...of medical research at Acceleron Pharma Inc. (NASDAQ:XLRN).TARGETSFASN (FAS) – Fatty acid synthase BC Staff Dynavax Technologies Corp. Avrobio Inc. Imago BioSciences Inc. ONL...
BioCentury | Nov 20, 2020
Finance

Nov. 19 Quick Takes: Olema’s IPO, plus venture rounds for Imago, Medable,  China deal for AUM-Newsoara and Qiming’s $1.2B fund

...it raised a $54 million crossover round in July.Imago raises $80M series CMyeloproliferative disease company Imago BioSciences Inc....
...Estrogen receptor 2LSD1 (KDM1A) – Lysine-specific demethylase 1 BC Staff Medable Inc. Olema Pharmaceuticals Inc. AUM Biosciences Pte. Ltd. Imago BioSciences Inc. Newsoara...
BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

...see "STING Start-Up STipe First to Emerge from Novo Incubator" ). Bone marrow disease play Imago BioSciences Inc....
...Therapeutics Inc. TCR2 Therapeutics Inc. Five Prime Therapeutics Inc. Evelo Biosciences Inc. Ohana Biosciences Magenta Therapeutics Inc. Mesa Biotech Inc. Orexo AB STipe Therapeutics Imago BioSciences Inc. Cinclus...
BioCentury | Nov 5, 2019
Company News

Management tracks: Santhera, Acadia, Aeglea, Entrada, Kleo, Laboratory for Advanced Medicine, Imago, Glympse and Cognition

...was EVP and general manager of AncestryDNA subsidiary of Ancestry LLC. Bone marrow disease play Imago BioSciences Inc....
...CFO. He was EVP of finance at Enzo Biochem Inc. (NYSE:ENZ). BioCentury Staff Cognition Therapeutics Inc. Glympse Bio Inc. Imago BioSciences Inc. Laboratory...
BioCentury | Jul 19, 2019
Company News

Management tracks: Iovance, ViiV, Hercules, Pappas and more

...and hired Alain Delcayre as SVP of research. Rienhoff is the founder and CEO of Imago BioSciences Inc....
BioCentury | Mar 21, 2019
Financial News

Imago to deploy $40M series B for Phase II trials

...to support completing Phase II trials of its lead compound, IMG-7289, for hematological indications. An Imago BioSciences Inc....
...Ventures Fund and Clarus Ventures. Omega Funds' Dina Chaya will join Imago's board. Sandi Wong, Staff Writer IMG-7289 Imago BioSciences Inc. Omega...
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...Ricolinostat (ACY-1215) Histone deacetylase 6 (HDAC6) Peripheral neuropathy Start Phase II October 2017 Undisclosed Undisclosed Imago BioSciences Inc....
BioCentury | Nov 10, 2016
Clinical News

IMG-7289: Ph I/II started

...I portion will identify the selected dose of IMG-7289 for the dose-expansion Phase II portion. Imago BioSciences Inc....
...leukemia (AML) and myelodysplastic syndrome (MDS) Endpoint: Safety; pharmacokinetics Status: Phase I/II started Milestone: NA Alicia Parker IMG-7289 Imago BioSciences Inc. Lysine-specific...
BioCentury | Jun 15, 2015
Finance

Products, hold the platform

...three investments - all on the traditional venture side. These include Annexon Bioscience Inc. , Imago BioSciences Inc....
...Avillion LLP, London, U.K. Clarus Ventures, Cambridge, Mass. Eisai Co. Ltd. (Tokyo:4523; Osaka:4523), Tokyo, Japan Imago BioSciences Inc....
BioCentury | Nov 10, 2014
Finance

Imago-in' places

...The team at Imago BioSciences Inc. raised a $26.5 million series A round geared to helping them repeat...
Items per page:
1 - 10 of 12